Amphotericin B with and without itraconazole for invasive aspergillosis: A three-year retrospective study

International Journal of Infectious Diseases

Volumn 3, Issue 3, 1999, Pages 157-160

  Popp, Adrian I ^a   White, Mary H ^a   Quadri, Tariq ^a   Walshe, Louise ^a   Armstrong, Donald ^a  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

Author keywords

Amphotericin B; Aspergillosis; Combination; Itraconazole

Indexed keywords

AMPHOTERICIN B; ITRACONAZOLE;

ADULT; ARTICLE; ASPERGILLOSIS; ASPERGILLUS; CLINICAL ARTICLE; CONTROLLED STUDY; FEMALE; HUMAN; MALE; ORAL DRUG ADMINISTRATION; RETROSPECTIVE STUDY; TREATMENT OUTCOME;

EID: 0032874659     PISSN: 12019712     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1201-9712(99)90038-3     Document Type: Article

References (18)

1. Bodey GP, Vartivarian S. Aspergillosis. Eur J Clin Microbiol Infect Dis 1989; 8:413-437.
2. Denning DW, Follansbee S, Scolaro M, Norris S, Edelstein H, Stevens DA. Pulmonary aspergillosis in acquired immunodeficiency syndrome. N Engl J Med 1991; 324:654-662.
3. Wald A, Leisenring W, van Burik JA, Bowden RA. Epidemiology of Aspergillus infections in a large cohort of patients undergoing bone marrow transplantation. J Infect Dis 1997; 175:1459-1466.
4. Burch PA, Karp JE, Merz WG, Kullman JE, Fishman EK. Favorable outcome of invasive aspergillosis in patients with acute leukemia. J Clin Oncol 1987; 5:1985-1993.
5. Denning DW Therapeutic outcome in invasive aspergillosis. Clin Infect Dis 1996; 23:608-615.
6. Denning DW, Stevens DA. Antifungal and surgical treatment of invasive aspergillosis: review of 2121 published cases Rev Infect Dis 1990; 12:1147-1201.
7. Chryssanthou E. In vitro susceptibility of respiratory isolates of Aspergillus species to itraconazole and amphotericin B. Acquired resistance to itraconazole. Scand J Infect Dis 1997; 29:509-512.
8. Stevens DA, Lee JY, Hostetler JS, et al. Analysis of compassionate use of itraconazole therapy for invasive aspergillosis by the NIAID Mycoses Study Group criteria. Arch Int Med 1997; 157:1857-1862.
9. Lebeau B, Pelloux H, Pinel C, et al. Itraconazole in the treatment of aspergillosis: a study of 16 cases. Mycoses 1994; 37:171-179.
10. Arroyo J, Medoff G, Kobayashi GS. Therapy of murine aspergillosis with amphotericin B in combination with rifampin or 5-fluorocytosine. Antimicrob Agents Chemother 1977; 11:21-25.
11. Polak A Combination therapy of experimental candidiasis, cryptococcosis, aspergillosis, and wangiellosis in mice Chemotherapy 1987; 33:381-395.
12. Chitkara N, White M, Rosenberg A, Sun M, Armstrong D. Retrospective comparison of treatment with amphotericin B versus amphotericin B and rifampin for invasive aspergillosis. Presented at the Ninth International Symposium on Infections in the Immunocompromised Host, Assisi, Italy. June 23-26, 1996.
13. Schaffner A, Frick P. The effect of ketoconazole on amphotericin B in a model of disseminated aspergillosis. J Infect Dis 1985; 151:902-910.
14. Schaffner A, Bohler A. Amphotericin B refractory aspergillosis after itraconazole: evidence of significant antagonism Mycoses 1993; 36:421-424.
15. Denning D, Lee J, Hostetler JS, et al. NLAID Mycoses Study Group multicenter trial of oral itraconazole therapy for invasive aspergillosis. Am J Med 1994; 97:135-144.
16. Sirio CA, Knaus WA. Triage and assessment of severity of illness. In: Hall J, Schmidt G, Wood L, eds Principles of critical care. New York: McGraw-Hill, 1992:551-557.
17. Gallis HA, Drew RH, Pickard WW. Amphotericin B: 30 years of clinical experience. Rev Infect Dis 1990; 12:308-329.
18. Daneshmend TK, Warnoch DW. Clinical pharmacokinetics of systemic antifungal drugs. Clin Pharmacokinet 1983; 8:17-42.